Connect with us

Hi, what are you looking for?

Right Decision NowRight Decision Now

Business

Ex-army pilot Peter Dilnot tops FTSE 100 ‘fat cat’ pay list with £45m package

Former army helicopter pilot Peter Dilnot has taken the top spot in the FTSE 100’s executive pay league, earning £45 million last year and overtaking AstraZeneca’s Pascal Soriot in Business Matters’ annual Fat Cat Files survey.

Former army helicopter pilot Peter Dilnot has taken the top spot in the FTSE 100’s executive pay league, earning £45 million last year and overtaking AstraZeneca’s Pascal Soriot in Business Matters’ annual Fat Cat Files survey.

Dilnot, 55, who runs aerospace engineer Melrose, shared in one of the largest boardroom payouts in UK corporate history after he and three other executives received a combined £208 million through a long-term share scheme agreed five years ago. The plan was triggered after the group hit performance targets, awarding Dilnot a one-off £43 million bonus alongside his salary and other benefits.

The huge awards mean Melrose has replaced Tesco as the FTSE 100 company with the largest pay gap between its chief executive and an average employee. Dilnot and predecessor Simon Peckham – who stood down in March 2024 with a £58 million payout – were each paid 1,112 times more than the £53,000 earned by the typical Melrose worker.

The two other executives in the scheme, Christopher Miller and Geoffrey Martin, took home £50 million and £57 million respectively.

Melrose, which owns the GKN aerospace business, has more than doubled its market value to £7.5 billion since the bonus plan was set, boosted by the 2018 acquisition of GKN and the demerger of its automotive arm into Dowlais.

Dilnot’s rise to the top ends Pascal Soriot’s reign as the UK’s highest-paid blue chip CEO. The AstraZeneca boss saw his pay fall from £16.9 million to £14.7 million last year after the company’s stock rally slowed following its Covid vaccine success.

Soriot now sits third, behind Pearson chief Omar Abbosh, who earned £16.3 million in 2024 – largely due to a buyout from his Microsoft contract.

Not all FTSE bosses saw increases: Rolls-Royce chief Tufan Erginbilgic’s total pay fell to £4.1 million from £13.6 million, reflecting the absence of a one-off £7.5 million award he received on joining from BP.

Emma Walmsley remains the highest-paid female CEO in the FTSE 100, earning £10.6 million at GlaxoSmithKline, down from £12.7 million. However, her 2025 package could reach £22 million under a new US-style remuneration scheme.

Melrose’s bonus scheme provoked one of the largest shareholder revolts in recent years, echoing the uproar over the £75 million Persimmon payout to Jeff Fairburn in 2018. That rebellion was advisory rather than binding but highlighted ongoing tensions over London-listed executive pay levels.

Some City figures argue UK pay is too low to compete globally. AstraZeneca, valued at £175 billion, is among several blue chips exploring a move to New York, where executive pay packages tend to be significantly higher.

Read more:
Ex-army pilot Peter Dilnot tops FTSE 100 ‘fat cat’ pay list with £45m package

    You May Also Like

    Stocks

    The market sell-off continued in earnest after a brief respite on Friday. Uncertainty of geopolitical tensions and tariff talk has spooked the market and...

    World News

    SEOUL – South Korea’s Constitutional Court will begin on Monday reviewing the impeachment of President Yoon Suk Yeol over his Dec. 3 martial law attempt, while investigators said...

    World News

    WASHINGTON – Federal workers faced fresh uncertainty about their futures on Tuesday after Elon Musk gave them “another chance” to respond to his ultimatum that they...

    World News

    BRASILIA – Brazil Prosecutor General Paulo Gonet decided not to charge former President Jair Bolsonaro with fraud in his vaccination records, asking the Supreme Court to...

    Disclaimer: rightdecisionnow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 rightdecisionnow.com | All Rights Reserved